[Polycystic ovaries in 2001: physiology and treatment].
Clinical characteristics of PCOS Syndrome Two fundamental characteristics: hyperandrogenism and anovulation which lead to hirsutism and oligo-or amenorrhea. Other features include obesity, acanthosis nigricans, and metabolic disruption (insulin resistance with hyperinsulinemia, glucose intolerance, or type II diabetes mellitus). Complementary tests Serum testosterone and DHEA-S levels: to exclude androgen-producing tumors. Serum 17-hydroxyprogesterone level: to exclude congenital adrenal hyperplasia, 21-hydroxylase deficiency. Ultrasound: increased size of the ovaries and central stroma with presence of peripheral follicular cysts (8-10) measuring about 8 mm in diameter. Pathophysiology Therapeutic approaches Therapeutic approaches
Chang
R J
RJ
Department of Reproductive Medicine, University of California, San Diego.
D019326:17-alpha-Hydroxyprogesterone / Q000097:blood; D000726:Androgen Antagonists / Q000627:therapeutic use; D003276:Contraceptives, Oral / Q000627:therapeutic use; D019314:Dehydroepiandrosterone Sulfate / Q000097:blood; D003937:Diagnosis, Differential; D015444:Exercise; D005260:Female; D006801:Humans; D007031:Hypothalamus / Q000503:physiopathology; D010053:Ovary / Q000000981:diagnostic imaging / Q000503:physiopathology; D010902:Pituitary Gland / Q000503:physiopathology; D011085:Polycystic Ovary Syndrome / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy*; D013739:Testosterone / Q000097:blood; D014463:Ultrasonography; D015431:Weight Loss
D000726:Androgen Antagonists; D003276:Contraceptives, Oral; D013739:Testosterone; D019314:Dehydroepiandrosterone Sulfate; D019326:17-alpha-Hydroxyprogesterone